Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Harmony Biosciences Holdings (HRMY)

Harmony Biosciences Q4 revenue rises 20% to $201.3 million; 2025 guidance reiterated

Positive Impact 3 of 5 earnings Written later

Harmony Biosciences reported fourth-quarter and full-year 2024 results, with WAKIX net product revenue of $201.3 million for the quarter, up 20% from a year earlier, and $714.7 million for the year, up 23%. The company reiterated its 2025 WAKIX net revenue guidance of $820 million to $860 million and said it reached a settlement in its first generic patent litigation. Quarterly GAAP diluted earnings per share were $0.85, up from $0.45, while full-year 2024 GAAP diluted EPS was $2.51, up from $2.13.

Key points

  • Q4 2024 net product revenue was $201.3 million, compared with $168.4 million in Q4 2023.
  • Q4 2024 GAAP net income was $49.5 million, or $0.85 per diluted share, versus $26.6 million, or $0.45, a year earlier.
  • Full-year 2024 net product revenue was $714.7 million; 2025 WAKIX net revenue guidance is $820 million to $860 million, reiterated, not changed.
  • Full-year 2024 GAAP net income was $145.5 million, or $2.51 per diluted share, including a $25.5 million upfront licensing fee and a $17.1 million IPR&D charge within R&D expenses.

The filing

CompanyHarmony Biosciences Holdings (HRMY)
Form8-K, current report
Filed with the SECFeb 25, 2025, 7:45 AM ET
Accession number0001558370-25-001439

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:54 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 25, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.